Bumetanide considered effective in the treatment of genetic Alzheimer's by the end of 2026?
Santé et médecineOne-Off2mois
FutuurVérifier la disponibilitéDonnées de résolution vérifiéesProbabilité implicite actuelle
Non 93%
Non 93%Qualité du marché
31 / 100
Faible qualitéVolume 24h
—
Liquidité
229,9 €
Faible liquiditéTraders
9
Commentaires
1
Données du marché
Mis à jour il y a 1 minute
Tendances
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
Règles
Drug repositioning is a common technique in research, where drugs that have already been approved to treat a certain disease are used to treat different diseases.
- By cross-referencing information from various sources, scientists in the United States have arrived at a drug that might be repositioned to treat Alzheimer's disease in patients with genetic mutations that increase the risk of developing the disease.
- According to their studies, Bumetanide - a diuretic drug - managed to reduce learning deficits in mice, and showed positive effects in human neurons in vitro.
- The next step was to analyze the medical records of more than 5 million adult patients, which led to the observation that the development of Alzheimer's disease was lower among those who made use of the diuretic drug.
- Despite the encouraging news, more tests are still needed to validate such a hypothesis.
- The next step for researchers will be to conduct randomized clinical trials to demonstrate the efficacy of bumetanide against genetic Alzheimer's disease.